Last reviewed · How we verify
FFP and Cryoprecipitate
FFP (Fresh Frozen Plasma) and Cryoprecipitate are blood products that replace deficient clotting factors and fibrinogen to restore hemostatic function.
FFP (Fresh Frozen Plasma) and Cryoprecipitate are blood products that replace deficient clotting factors and fibrinogen to restore hemostatic function. Used for Acute bleeding due to coagulation factor deficiency, Fibrinogen replacement in hypofibrinogenemia, Disseminated intravascular coagulation (DIC).
At a glance
| Generic name | FFP and Cryoprecipitate |
|---|---|
| Also known as | FFP |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Blood product / Hemostatic agent |
| Modality | Biologic |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
FFP is a plasma product containing all vitamin K-dependent factors, fibrinogen, and other coagulation proteins, used to correct multiple factor deficiencies. Cryoprecipitate is a concentrated source of fibrinogen, von Willebrand factor, factor VIII, fibronectin, and factor XIII, used primarily to restore fibrinogen levels in bleeding or coagulopathic states. Together, they address acute coagulation defects through factor replacement.
Approved indications
- Acute bleeding due to coagulation factor deficiency
- Fibrinogen replacement in hypofibrinogenemia
- Disseminated intravascular coagulation (DIC)
- Massive transfusion protocols
- Perioperative hemostasis management
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Fluid overload
- Infection transmission (rare with modern screening)
- Thrombosis
Key clinical trials
- Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures (NA)
- Adjusted Fibrinogen Replacement Strategy (PHASE3)
- Rotational Thromboelastometry [ROTEM] vs Thromboelastography [TEG] Guided Blood Component Use in Patients With Cirrhosis of Liver With Non-variceal Bleeding. (NA)
- Platelet Transfusion During Neonatal Open Heart Surgery (PHASE4)
- Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial (NA)
- Patient Blood Management for Massive Obstetric Hemorrhage (NA)
- The Trauma- Formula-Driven Versus Lab-Guided Study (TRFL Study) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: